Abstract Background Persistent pulmonary hypertension in the neonate PPHN is associated with high mortality. Currently, the therapeutic mainstay for PPHN consists of assisted ventilation and administration of inhaled nitric oxide iNO . However, nitric oxide is costly, and its use may not be appropriate in resource p